Precigen, Inc. (PGEN) stock
PGENNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 6/30239% above fair value
$4.54−0.12 (-2.58%)
Close on Nov 13, 2026Market cap $1.63BP/E 113.5Yield –
Precigen EV/EBITDA
EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.
No ev/ebitda figures for Precigen
Precigen has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.
See a number that looks wrong?